No products in the cart.
Pre-made Ladiratuzumab benchmark antibody ( Whole mAb ADC, anti-SLC39A6 therapeutic antibody, Anti-LIV-1/LIV1/ZIP6 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-291
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ladiratuzumab biosimilar, Whole mAb ADC, Anti-SLC39A6 Antibody: Anti-LIV-1/LIV1/ZIP6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ladiratuzumab vedotin, also known as SGN-LIV1A and anti-LIV-1 ADC, is a humanized antibody conjugated through a proteolytically cleavable linker to MMAE to Zinc transporter LIV-1 (SLC39A6).
| Products Name (INN Index) | Pre-Made Ladiratuzumab biosimilar, Whole mAb ADC, Anti-SLC39A6 Antibody: Anti-LIV-1/LIV1/ZIP6 therapeutic antibody |
|---|---|
| INN Name | Ladiratuzumab |
| Target | SLC39A6 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Merck & Co,Quantum Leap Healthcare Collaborative,Seattle Genetics |
| Conditions Approved | NA |
| Conditions Active | Breast cancer |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SLC39A6 |
| Package |
Previous slide
Next slide
